全文获取类型
收费全文 | 25447篇 |
免费 | 2081篇 |
国内免费 | 469篇 |
专业分类
耳鼻咽喉 | 94篇 |
儿科学 | 650篇 |
妇产科学 | 459篇 |
基础医学 | 1441篇 |
口腔科学 | 871篇 |
临床医学 | 3419篇 |
内科学 | 4582篇 |
皮肤病学 | 523篇 |
神经病学 | 1093篇 |
特种医学 | 605篇 |
外国民族医学 | 2篇 |
外科学 | 1708篇 |
综合类 | 2556篇 |
现状与发展 | 7篇 |
一般理论 | 1篇 |
预防医学 | 5172篇 |
眼科学 | 606篇 |
药学 | 2020篇 |
26篇 | |
中国医学 | 975篇 |
肿瘤学 | 1187篇 |
出版年
2024年 | 62篇 |
2023年 | 481篇 |
2022年 | 687篇 |
2021年 | 1300篇 |
2020年 | 1419篇 |
2019年 | 1096篇 |
2018年 | 1067篇 |
2017年 | 978篇 |
2016年 | 966篇 |
2015年 | 884篇 |
2014年 | 1626篇 |
2013年 | 2439篇 |
2012年 | 1280篇 |
2011年 | 1442篇 |
2010年 | 1244篇 |
2009年 | 1142篇 |
2008年 | 1124篇 |
2007年 | 1147篇 |
2006年 | 1111篇 |
2005年 | 909篇 |
2004年 | 795篇 |
2003年 | 704篇 |
2002年 | 629篇 |
2001年 | 498篇 |
2000年 | 372篇 |
1999年 | 366篇 |
1998年 | 324篇 |
1997年 | 241篇 |
1996年 | 264篇 |
1995年 | 184篇 |
1994年 | 141篇 |
1993年 | 151篇 |
1992年 | 117篇 |
1991年 | 102篇 |
1990年 | 80篇 |
1989年 | 81篇 |
1988年 | 93篇 |
1987年 | 63篇 |
1986年 | 52篇 |
1985年 | 62篇 |
1984年 | 54篇 |
1983年 | 41篇 |
1982年 | 37篇 |
1981年 | 38篇 |
1980年 | 20篇 |
1979年 | 20篇 |
1978年 | 11篇 |
1977年 | 18篇 |
1976年 | 11篇 |
1975年 | 8篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
41.
Paroxysmal dyskinesias (PxDs) are involuntary, episodic movements that include paroxysmal kinesigenic (PKD), paroxysmal nonkinesigenic (PNKD), and paroxysmal hypnogenic (PHD) varieties. Although most PxDs are primary (idiopathic or genetic), we found 17 of our 76 patients with PxD (22%) to have an identifiable cause for their PxD (10 men; mean age, 41.4 years). Causes included peripheral trauma (in three patients), vascular lesions (in four), central trauma (in four), kernicterus (in two), multiple sclerosis (in one), cytomegalovirus encephalitis (in one), meningovascular syphilis (in one), and migraine (in one). The latency from insult to symptom onset ranged from days (trauma) to 18 years (kernicterus), with a mean of 3 years. Nine patients had PNKD, two had PKD, five had mixed PKD/PNKD, and one had PHD. Hemidystonia was the most common expression of the paroxysmal movement disorder, present in 11 patients. Both of the patients with PKD had symptom durations of <5 minutes. Symptom duration ranged from 10 seconds to 15 days for PNKD and from 5 minutes to 45 minutes for mixed PKD/PNKD. There were no uniformly effective therapies, but anticonvulsant drugs, clonazepam, and botulinum toxin injections were the most beneficial. Awareness of the variable phenomenology and the spectrum of causes associated with secondary PxD will allow for more timely diagnosis and early intervention. 相似文献
42.
Akihiko Bo Shinichi Imura Hironori Omori Yasuhiro Okumura Masao Ando Hisatoshi Baba Patrick White Al Zarnowski 《Journal of orthopaedic science》1997,2(5):301-312
The fit and fill of the femoral canal are critical to the success of cementless femoral stems in total hip arthroplasty. It
is difficult for conventional stems to provide a good fit and fill for the femora of patients with secondary osteoarthritis.
Based on measurements of 100 femora of these patients, we designed two types of Fukui Medical School (FMS) stems with a proximal
lateral flare that differed in the medial radius. We compared the fit and fill of the FMS stems with those of four conventional
stems, using computer simulation. The mean proximal fit and total fit of the FMS stems were 46% and 53% respectively, a significant
improvement compared with the other stems examined. The mean fill of FMS stems was 82% at the lower end of the lesser trochanter
and 84% at the upper end of the isthmus, values that were significantly higher than those of the other stems. Since September
1995, we have implanted FMS stems in 15 hips with secondary osteoarthritis. Radiographic evaluations showed that the canal
fill of the FMS stems was significantly greater in the proximal femur compared with other stems previously inserted at our
department.
A summary of this paper was presented at the 9th Symposium on Computer-Assisted Radiology; June 1995, Berlin, and at the 8th
International Symposium on Technology in Arthroplasty; September 1995, Puerto Rico. 相似文献
43.
颈丛阻滞常可引起心率增快 ,血压增高 ,被认为是颈动脉窦及迷走神经被阻滞 ,交感神经活性增强所致 [1 ]。我们采用艾司洛尔预注射的方法 ,抑制颈丛阻滞后的心血管副反应 ,取得了良好的效果 ,现介绍如下。1 临床资料和方法1.1 一般资料 选择 ASA I~ 级 ,择期行甲状腺瘤或囊 相似文献
44.
S B Wieslander B T Mortensen L Binderup N I Nissen 《European journal of haematology》1987,39(1):35-38
10 patients with CLL and 2 with CML were treated with gradually increasing doses of 1 alpha(OH)D3, up to 4 micrograms daily during 6 wk. 3 patients with preleukemia and 1 with myelofibrosis were treated with 2 micrograms daily of 1 alpha(OH)D3 for a prolonged period up to 17 wk. The treatment with 1 alpha (OH)D3 did not result in changes of disease parameters in any of the patients under study. Receptor studies for 1,25(OH)2D3 were performed in 8 CLL patients and revealed only 1 patient with increased specific receptor binding capacity. The maximum tolerable dose of 1 alpha(OH)D3 varied individually, but was in the range of 2-4 micrograms daily. 相似文献
45.
调整给药时间减轻顺铂肾毒性的研究 总被引:7,自引:0,他引:7
目的 观察不同给药时间对顺铂肾毒性的影响。 方法 1 6例癌症患者分为两组各 8例 ,分别在上午 1 0时或下午 8时静滴 6 0mg m2 顺铂 ,3~ 4周后作第 2周期化疗时交换给药时间 ,以尿 β2 微球蛋白浓度作为肾小管功能改变的指标。 结果 治疗前两组的尿 β2 微球蛋白浓度均在 2 0 0 μg L以下。治疗后 ,上午 1 0时给药组的尿β2 微球蛋白浓度在第 1周期为 4 96± 6 6 μg L ,第 2周期为 5 0 4± 74 μg L ,下午 8时给药组分别为 2 77± 4 3μg L(t=3.6 6 ,P <0 .0 1 )和 2 83± 39μg L(t=3.6 3,P <0 .0 1 )。 结论 不同时间给药对顺铂的肾毒性有显著影响 ,下午 8时给药可明显减轻顺铂的肾毒性。 相似文献
46.
W. A. A. Tjalma M. Arbyn† J. Paavonen‡ T. R. Van Waes & J. J. Bogers§ 《International journal of gynecological cancer》2004,14(5):751-761
Persistent infection with one of the oncogenic human papillomavirus (HPV) types is a necessity for the development of cervical cancer. By HPV vaccination, cervical cancer could become a very rare disease. Two types of HPV vaccines can be distinguished: (i) therapeutic vaccines which induce cellular immunity targeted against epithelial cells infected with HPV and (ii) prophylactic vaccines inducing virus-neutralizing antibodies protecting against new but not against established infections. At present, several vaccines have been developed and tested in clinical trials. The vaccines are generally well tolerated and highly immunogenic. The current clinical data indicate that prophylactic vaccines are very effective against new persistent infections and the development of cervical intraepithelial lesions. The protection is type specific. However, the follow-up of the vaccination trials is still short. The effect of HPV vaccines on future cancer incidence will only be known after decades of follow-up. This article will address the status of recently terminated phase II and currently running phase III trials with prophylactic HPV vaccines. 相似文献
47.
Leslee J. Shaw Romalisa Miranda-Peats Piotr Slomka John Friedman Sean W. Hayes Daniel S. Berman Gary V. Heller Marcin Dada William E. Boden Paul Casperson Robert A. O’Rourke Ronald Schwartz William S. Weintraub David J. Maron Spencer King Koon Teo Pamela Hartigan 《Journal of nuclear cardiology》2006,13(5):685-698
Background Stress gated myocardial perfusion single photon emission computed tomography (gSPECT) is increasingly used before and after
intercurrent therapeutic intervention and is the basis for ongoing evaluation in the Department of Veterans Affairs clinical
outcomes utilizing revascularization and aggressive drug evaluation (COURAGE) trial.
Methods and Results The COURAGE trial is a North American multicenter randomized clinical trial that enrolled 2287 patients to aggressive medical
therapy vs percutaneous coronary intervention plus aggressive medical therapy. Three COURAGE nuclear substudies have been
designed. The goals of substudy 0 are to examine the diagnostic accuracy of the extent and severity of inducible ischemia
at baseline in COURAGE patients compared with patient symptoms and quantitative coronary angiography and to explore the relationship
between inducible ischemia and the benefit from revascularization when added to medical therapy. Substudy 1 will correlate
the extent and severity of provocative ischemia with the frequency, quality, and instability of recurrent symptoms in postcatheterization
patients. Substudy 2 (n _ 300) will examine the usefulness of sequential gSPECT monitoring 6 to 18 months after therapeutic
intervention. Together, these nuclear substudies will evaluate the role of gSPECT to determine the effectiveness of aggressive
risk-factor modifications, lifestyle interventions, and anti-ischemic medical therapies with or without revascularization
in reducing patients’ ischemic burdens.
Conclusions The unfolding of evidence on the application of gSPECT in trials such as COURAGE defines a new era for nuclear cardiology.
We hope the evidence that emerges from the COURAGE trial will further establish the role of nuclear imaging in the evidence-based
management of patients with stable coronary disease.
The COURAGE trial was supported by the Cooperative Studies Program of the Department of Veterans Affairs Office of Research
and Development in collaboration with the Canadian Institutes of Health Research. Unrestricted research grants were obtained
from Merck & Co; Pfizer Pharmaceuticals; Bristol-Myers Squibb Medical Imaging; Astellas Pharma; Kos Pharmaceuticals; Data
Scope; Astra Zeneca Pharmaceuticals; Astra-Zeneca-Canada; Schering-Plough Coorporation, Ltd; Sanofi-Aventis, Inc; First Horizon;
and GE Healthcare. All industrial funding for this trial was directed through the Department of Veterans Affairs. Additional
funding for this substudy was provided by grants to the Department of Veterans Affairs and Canadian Institutes of Health Research
from Astellas Pharma and Bristol-Myers-Squibb Medical Imaging. 相似文献
48.
Judith D. Goldberg Arnold I. Weiss Kenneth J. Koury 《Journal of clinical periodontology》1986,13(5):411-414
In order to make effective use of the statistical theory of design of clinical trials for chronic diseases such as periodontal disease, certain issues must be considered. Any clinical trial requires that the disease definition be well-specified; that patient eligibility be explicit; that the observation times be explicit; that the duration and endpoint of therapy be specified; that the duration of subsequent followup observation be specified; and that the unit of observation (e.g., tooth, set of teeth, patient) be defined. In a chronic disease, the potential biases that can readily be introduced by self-selection of patients who enter the trial and/or who return for subsequent observation become more important, because subjects are required to remain on treatment and/or observation for prolonged periods. Further, the cyclical nature of some chronic diseases may require special attention to baseline definitions of active disease and disease outcome. These issues are illustrated with examples from clinical trials of hypertension, breast cancer screening, and Polycythemia Vera. Implications for periodontal disease are discussed. 相似文献
49.
固定剂量复合剂在省结核病防治规划中应用的研究 总被引:2,自引:0,他引:2
目的 研究固定剂量复合剂在省结核病防治规划中应用的可行性.方法 将初治涂阳肺结核病人按登记序号单双分入研究组和对照组.用对照研究方法对两组的完成治疗率、治疗效果、治疗依从性和不良反应等情况进行分析.结果 研究组和对照组在性别、年龄、体重、完成治疗率、督导管理方式和治疗依从性等方面差异无显著性(P值均>0.05).研究组的2、3个月未痰菌阴转率和治愈率分别为87.0%、93.5%和93.5%,对照组的2、3个月未痰菌阴转率和治愈率分别为89.4%、93.5%和87.0%,两组间的疗效差异无显著性(P值均>0.05).除因链霉素引起的耳鸣(精确概率法P=0.024)外,两组其他不良反应症状出现的比例都无显著性差异(P值均>0.05).结论 在结核病防治规划中推广应用固定剂量复合剂是可行的. 相似文献